Quellen:
Verbrugge, Frederik H, and Venu Menon. “In perspective: Torsemide Comparison With Furosemide For Management of Heart Failure (TRANSFORM-HF) trial.” European heart journal. Acute cardiovascular care, zuac144. 9 Nov. 2022, doi:10.1093/ehjacc/zuac144
https://pubmed.ncbi.nlm.nih.gov/36351030/
Transform HF (transformhfstudy.org)
https://transformhfstudy.org/
Kalra, Paul R et al. “Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.” Lancet (London, England), S0140-6736(22)02083-9. 4 Nov. 2022, doi:10.1016/S0140-6736(22)02083-9
https://pubmed.ncbi.nlm.nih.gov/36347265/
Gillmore, Julien D. „CRISPR/Cas9-based gene editing in patients with transthyretin amyloid cardiomyopathy“. Presented at the AHA Scientific Sessions 2022
https://ipccs.org/2022/11/06/crispr-cas9-based-gene-editing-in-patients-with-transthyretin-amyloid-cardiomyopathy/
Lee, Douglas S et al. “Trial of an Intervention to Improve Acute Heart Failure Outcomes.” The New England journal of medicine, 10.1056/NEJMoa2211680. 5 Nov. 2022, doi:10.1056/NEJMoa2211680
https://pubmed.ncbi.nlm.nih.gov/36342109/